However, a lower mortality due to CVDs was associated with 5-ARI ever-users who had > 5,840 cDDDs of cumulative dose (aHR, 0.260; 95% CI, 0.101–0.669) and > 1,460 cDDDs/year of average cumulative dose (aHR, 0.173; 95% CI, 0.048–0.629), with a marginally significant P -for-trend.
← all excerpts
Differential association between cumulative dose of 5α-reductase inhibitors and mortality.
1
—
—